 |
0 Diseases |  |
643 Trials |
|
643 Trials |  |
26774 News |  |
| «12...496497498499500501502503504505506507508» |
- || bortezomib / Generic mfg., doxorubicin hydrochloride / Generic mfg., gemcitabine / Generic mfg.
Enrollment closed, Combination therapy, Metastases: Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors (clinicaltrials.gov) - Nov 5, 2012
P1, N=80, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting
- | evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
New P1 trial: TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma (clinicaltrials.gov) - Nov 4, 2012
P1, N=20, Not yet recruiting, Sponsor: Scripps Clinic Cancer Center
- | P2 data: CHEMO-T: CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study (clinicaltrials.gov) - Oct 30, 2012
P2, N=186, Recruiting, Sponsor: Royal Marsden NHS Foundation Trust
- |||||| Adcetris (brentuximab vedotin) / Takeda, Pfizer
Enrollment open, Metastases: ECHELON-1 : A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma (clinicaltrials.gov) - Oct 28, 2012
P3, N=1040, Recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | cisplatin / Generic mfg., cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment open, BRCA Biomarker: Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa (clinicaltrials.gov) - Oct 25, 2012
P2, N=166, Recruiting, Sponsor: Beth Israel Deaconess Medical Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Adcetris (brentuximab vedotin) / Takeda, Pfizer
New P3 trial, Metastases: ECHELON-1 : A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma (clinicaltrials.gov) - Oct 21, 2012
P3, N=1040, Recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
- Enrollment change, Metastases: Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium (clinicaltrials.gov) - Oct 17, 2012
P2, N=65, Completed, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting N=49 --> 65
- | cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg., epirubicin / Generic mfg.
Enrollment open: ACE500: Trial of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma (clinicaltrials.gov) - Oct 16, 2012
P2/3, N=450, Recruiting, Sponsor: Nihon University
N=49 --> 65 Not yet recruiting --> Recruiting
- paclitaxel / Generic mfg.
Trial completion, Metastases: Radiation Therapy Plus Paclitaxel in Treating Patients With Stage IIB or Stage III Breast Cancer (clinicaltrials.gov) - Oct 15, 2012
P2, N=46, Completed, Sponsor: University of Southern California
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- bortezomib / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment closed, Combination therapy: This Study Plans to Assess the Response of PAD Treatment to VAD or VAD-like Treatment in Patients Who Have Relapsed or Refractory Myeloma (clinicaltrials.gov) - Oct 11, 2012
P2, N=69, Active, not recruiting, Sponsor: All Ireland Cooperative Oncology Research Group
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Genasense (oblimersen) / Genta
Trial termination, Metastases: Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Oct 10, 2012
P=N/A, N=37, Terminated, Sponsor: University of Nebraska
Recruiting --> Active, not recruiting Recruiting --> Terminated; Manufacturer is no longer making the drug.
- | Herceptin (trastuzumab) / Roche
Enrollment change, Surgery: Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression (clinicaltrials.gov) - Oct 10, 2012
P2, N=30, Recruiting, Sponsor: University of Kansas
Recruiting --> Terminated; Manufacturer is no longer making the drug. N=50 --> 30
- Genasense (oblimersen) / Genta
Enrollment change, Metastases: Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Oct 10, 2012
P=N/A, N=37, Terminated, Sponsor: University of Nebraska
N=50 --> 30 N=70 --> 37
- | Halaven (eribulin mesylate) / Eisai
New P2 trial, Metastases: Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer (clinicaltrials.gov) - Oct 10, 2012
P2, N=50, Active, not recruiting, Sponsor: National Surgical Adjuvant Breast and Bowel Project (NSABP)
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Tomudex (raltitrexed) / Pfizer, AstraZeneca
New P2 trial, Metastases: Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic (clinicaltrials.gov) - Oct 9, 2012
P2, N=80, Recruiting, Sponsor: Centro Nacional de Investigaciones Oncologicas CARLOS III
- | Enrollment open: High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN) (clinicaltrials.gov) - Oct 9, 2012
P3, N=2000, Recruiting, Sponsor: St. Anna Kinderkrebsforschung
N=70 --> 37 Not yet recruiting --> Recruiting
- Rituxan (rituximab) / Roche
Trial withdrawal: Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma (clinicaltrials.gov) - Oct 8, 2012
P2, N=0, Withdrawn, Sponsor: Kristie Blum
Not yet recruiting --> Recruiting Not yet recruiting --> Withdrawn
- Rituxan (rituximab) / Roche
Enrollment change: Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma (clinicaltrials.gov) - Oct 8, 2012
P2, N=0, Withdrawn, Sponsor: Kristie Blum
Not yet recruiting --> Withdrawn N=24 --> 0
- methotrexate IV / Generic mfg., cytarabine / Generic mfg.
Enrollment change: Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma (clinicaltrials.gov) - Oct 4, 2012
P2, N=19, Completed, Sponsor: M.D. Anderson Cancer Center
N=24 --> 0 N=45 --> 19
- | Clinical: Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Oct 4, 2012
P3, N=61, Completed, Sponsor: M.D. Anderson Cancer Center
N=45 --> 19 N=218 --> 61
- || New P3 trial: High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN) (clinicaltrials.gov) - Oct 4, 2012
P3, N=2000, Recruiting, Sponsor: St. Anna Kinderkrebsforschung
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Metastases: S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer (clinicaltrials.gov) - Oct 4, 2012
P3, N=399, Completed, Sponsor: Southwest Oncology Group
N=218 --> 61 Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche, Neulasta (pegfilgrastim) / Roche
Enrollment closed, Metastases: S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer (clinicaltrials.gov) - Oct 2, 2012
P2, N=200, Active, not recruiting, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | tamoxifen / Generic mfg.
Trial completion, Surgery: SWOG S8814: SWOG-8814 Tamoxifen With or Without Combination Chemotherapy in Postmenopausal Women Who Have Undergone Surgery for Breast Cancer (clinicaltrials.gov) - Oct 2, 2012
P3, N=1558, Completed, Sponsor: Southwest Oncology Group
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- paclitaxel / Generic mfg.
Trial completion, Surgery: Paclitaxel and Radiation Therapy in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer (clinicaltrials.gov) - Oct 2, 2012
P=N/A, N=38, Completed, Sponsor: Vanderbilt-Ingram Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Rituxan (rituximab) / Roche
Trial completion: S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma (clinicaltrials.gov) - Oct 2, 2012
P2, N=56, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | triciribine phosphate (PTX-200) / VioQuest, Prescient Therap
New P1 trial, Metastases: PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer (clinicaltrials.gov) - Sep 30, 2012
P1, N=46, Recruiting, Sponsor: Joseph Sparano
- |||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Biomarker, Enrollment open: GAINED: GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Sep 30, 2012
P3, N=670, Recruiting, Sponsor: The Lymphoma Academic Research Organisation
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg., docetaxel / Generic mfg.
New P2 trial, Surgery: GEIS: Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults (clinicaltrials.gov) - Sep 27, 2012
P2, N=43, Recruiting, Sponsor: Grupo Espanol de Investigacion en Sarcomas
- Trial completion: Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes (clinicaltrials.gov) - Sep 27, 2012
P2, N=16, Completed, Sponsor: Case Comprehensive Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- GM.CD40L cell vaccine / Cellular Biomedicine, H. Lee Moffitt Cancer Center and Research Institute
Enrollment change, Tumor cell: Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma (clinicaltrials.gov) - Sep 26, 2012
P2, N=43, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed N=60 --> 43
- doxorubicin hydrochloride / Generic mfg., docetaxel / Generic mfg.
Trial completion: Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer (clinicaltrials.gov) - Sep 23, 2012
P2, N=45, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
N=60 --> 43 Active, not recruiting --> Completed
- Herceptin (trastuzumab) / Roche
Enrollment closed: Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer (clinicaltrials.gov) - Sep 20, 2012
P=N/A, N=81, Active, not recruiting, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- etoposide oral / Generic mfg.
Trial termination, HEOR: Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Sep 19, 2012
P2/3, N=3, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated; low accrual
- Enrollment change: Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Sep 19, 2012
P2, N=25, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Terminated; low accrual N=82 --> 25
- cisplatin / Generic mfg., paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment change, Metastases: Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer (clinicaltrials.gov) - Sep 19, 2012
P2, N=141, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=82 --> 25 N=312 --> 141
- Trial completion: Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Sep 19, 2012
P2, N=25, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=312 --> 141 Active, not recruiting --> Completed
- cisplatin / Generic mfg., paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion, Metastases: Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer (clinicaltrials.gov) - Sep 19, 2012
P2, N=141, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Surgery: Combination Chemotherapy and Surgery With or Without G-CSF in Treating Patients With Osteosarcoma (clinicaltrials.gov) - Sep 19, 2012
P3, N=214, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | pamidronate disodium / Generic mfg.
Trial completion: Neoadjuvant and Adjuvant Pamidronate With Induction and Maintenance Chemotherapy in Treating Patients With Osteosarcoma (clinicaltrials.gov) - Sep 12, 2012
P2, N=75, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || New P3 trial: Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance (clinicaltrials.gov) - Sep 12, 2012
P3, N=406, Recruiting, Sponsor: Wuerzburg University Hospital
- Trial completion: Adjuvant Therapy for High-Risk Breast Cancer With Wkly Adriamycin & Oral Cytoxan With G-CSF for 12 Wks; Wkly Taxol x 12 (clinicaltrials.gov) - Sep 11, 2012
P2, N=80, Completed, Sponsor: University of Washington
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment change: Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Sep 5, 2012
P3, N=523, Recruiting, Sponsor: Cancer and Leukemia Group B
Active, not recruiting --> Completed N=170 --> 523
- Rituxan (rituximab) / Roche
Enrollment closed: Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma (clinicaltrials.gov) - Sep 5, 2012
P2, N=70, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=170 --> 523 Recruiting --> Active, not recruiting
- | Campath (alemtuzumab) / Sanofi
New P2 trial: PTCL-06: Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma (clinicaltrials.gov) - Sep 4, 2012
P2, N=92, Completed, Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- | everolimus / Generic mfg.
New P2 trial: EVACEL: Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors (clinicaltrials.gov) - Sep 3, 2012
P2, N=72, Recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
- Vegzelma (bevacizumab-adcd) / Celltrion, Avastin (bevacizumab) / Roche, Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
Enrollment closed, Surgery: Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - Sep 3, 2012
P2, N=445, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- doxorubicin hydrochloride / Generic mfg.
Clinical: Survival According to the Feeding Artery Obliteration by Chemoembolization for Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Aug 30, 2012
P=N/A, N=250, Recruiting, Sponsor: Hallym University Medical Center
- cisplatin / Generic mfg., paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
New P2 trial, BRCA Biomarker: BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy (clinicaltrials.gov) - Aug 23, 2012
P2, N=40, Recruiting, Sponsor: Russian Academy of Medical Sciences
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment closed, Metastases: Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors (clinicaltrials.gov) - Aug 23, 2012
P2, N=74, Active, not recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting